Weekly Investment Analysts’ Ratings Updates for Cencora (COR)

A number of research firms have changed their ratings and price targets for Cencora (NYSE: COR):

• 10/16/2026 – Cencora had its price target lowered by UBS Group AG from $430.00 to $400.00. They now have a “buy” rating on the stock.
• 10/12/2026 – Cencora had its price target raised by Robert W. Baird from $370.00 to $373.00. They now have an “outperform” rating on the stock.
• 10/7/2026 – Cencora had its price target raised by Leerink Partners from $380.00 to $388.00. They now have an “outperform” rating on the stock.
• 10/6/2026 – Cencora was upgraded by Weiss Ratings from “buy (b-)” to “buy (b)”.
• 9/8/2026 – Cencora had its “sector perform” rating reaffirmed by Royal Bank Of Canada. They now have a $330.00 price target on the stock.

Cencora Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, August 31st. Stockholders of record on Friday, August 14th were given a $0.60 dividend. The ex-dividend date of this dividend was Friday, August 14th. This represents a $2.40 annualized dividend and a dividend yield of 0.7%. Cencora’s dividend payout ratio is currently 17.83%.

Insider Activity at Cencora

In other news, EVP Elizabeth Campbell sold 11,300 shares of the firm’s stock in a transaction that occurred on Monday, August 24th. The stock was sold at an average price of $324.12, for a total value of $3,662,556.00. Following the completion of the transaction, the executive vice president owned 19,455 shares in the company, valued at $6,305,754.60. This trade represents a 36.74% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.38% of the stock is currently owned by insiders.

Cencora, formerly known as AmerisourceBergen, is a global pharmaceutical sourcing and distribution company. It provides branded, generic and specialty pharmaceuticals, over-the-counter products and related health care supplies to pharmacies, hospitals, health systems, physician practices and other health care providers.

The company also offers services to pharmaceutical and biotechnology manufacturers, including logistics, commercialization support, market access, consulting, clinical trial support and patient assistance programs.